Press Release
IB Communications
Tel +44 (0)20 89434685
title21@ibcomms.agency

Title21 Health Solutions Names Jonathan Wofford Chief Commercial Officer

- **Wofford brings extensive experience in software development and a deep understanding of the cell therapy/stem cell transplant fields as Title21 seeks to expand the reach of its cell and gene therapy business**
- **Latest C-suite addition since CEO Tony Pare joined in December**

Phoenix, AZ, April 2, 2025 – **Title21 Health Solutions**, the software innovators for meeting life science regulatory needs, announced the addition of Jonathan Wofford as the company's first Chief Commercial Officer (CCO) to oversee the company's products, sales, and marketing efforts. Wofford has over two decades of experience in the cell therapy and stem cell transplant fields focusing on clinical research and technology development. He launched a comprehensive commercial software platform for blood and marrow transplant programs and cellular processing laboratories, leading to the founding of Transtem LLC. He then spent over 12 years managing the development and introduction of technology solutions across the cell and gene therapy supply chain.

Wofford's work reflects a commitment to the groundbreaking new opportunities that Advanced Therapies offer for treating life-threatening diseases and disorders, and a recognition that to accelerate research and new therapy development, technology is essential in bridging the data gaps and integrating stakeholders across the product journey. "At Title21, I believe that we can create an integrated product ecosystem connected through centralized data management and driven by advanced analytics – through innovation we can accelerate therapy development and delivery and reach our ultimate goal of improving patient outcomes and quality of life".

"Jonathan will be a key addition to our leadership team as we build upon our history as innovators for the biotherapy industry," said Tony Pare, CEO of Title21 Health Solutions. "His deep expertise with both cell therapy and hematopoietic stem cell transplant will help us grow as we become an increasingly indispensable partner for our clients."

About Title21 Health Solutions
Title21 Health Solutions is an ArchiMed portfolio company. ArchiMed is a leading healthcare industry-focused growth equity enterprise based in New York and Lyon, France. Since 2001, Title21 Health Solutions has been dedicated to delivering easy-to-use, flexible, and integrated technology to support healthcare providers and the health sciences to achieve compliance, gain efficiencies and ensure high quality, ultimately, to support improvement in patient safety and care. The sole focus is developing technology to meet the specific needs of healthcare and life sciences firms, resulting in comprehensive solutions that are flexible to evolving business and regulatory requirements. Through the years, their partnerships with industry leaders have road-mapped their innovations to continue to meet the dynamic needs of the markets they serve. www.title21.com